-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASTCTChat Q1: How do the findings of this paper impact your survivorship plan? https://t.co/kgBOAbvN4P https://t.co/yloZjbWW5W
-
-
Mashup Score: 3Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors - 1 year(s) ago
Advances in hematopoietic cell transplantation (HCT) practices over the past 2 decades, particularly the introduction of reduced-intensity conditioning regimens and the improvement in palliative/supportive care services, have resulted in HCT becoming better tolerated in older patients (≥60 years) who were previously excluded from consideration for transplantation. Consequently, the upper age…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
#ASTCTChat Q3: Which (if any) HRQoL scales do you use routinely in your transplant program? https://t.co/kgBOAbvffh https://t.co/fxMWVyPfOj